Terms: = Ovarian cancer AND PSA AND Treatment
53 results:
1. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
Yong CM; Yehgambaram PAP; Lee SWH
PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
[TBL] [Abstract] [Full Text] [Related]
2. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate cancer.
Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H
Clin Cancer Res; 2023 Sep; 29(17):3292-3300. PubMed ID: 37339186
[TBL] [Abstract] [Full Text] [Related]
3. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract] [Full Text] [Related]
4. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
[TBL] [Abstract] [Full Text] [Related]
5. Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients.
Valle-Inclan JE; Stangl C; de Jong AC; van Dessel LF; van Roosmalen MJ; Helmijr JCA; Renkens I; Janssen R; de Blank S; de Witte CJ; Martens JWM; Jansen MPHM; Lolkema MP; Kloosterman WP
Genome Med; 2021 May; 13(1):86. PubMed ID: 34006333
[TBL] [Abstract] [Full Text] [Related]
6. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
[TBL] [Abstract] [Full Text] [Related]
7. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
Harrison RF; Cantor SB; Sun CC; Villanueva M; Westin SN; Fleming ND; Toumazis I; Sood AK; Lu KH; Meyer LA
Gynecol Oncol; 2021 Apr; 161(1):56-62. PubMed ID: 33536126
[TBL] [Abstract] [Full Text] [Related]
8. Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate cancer (PCa) Status.
Snider AJ; Seeds MC; Johnstone L; Snider JM; Hallmark B; Dutta R; Moraga Franco C; Parks JS; Bensen JT; Broeckling CD; Mohler JL; Smith GJ; Fontham ETH; Lin HK; Bresette W; Sergeant S; Chilton FH
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33007922
[TBL] [Abstract] [Full Text] [Related]
9. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
[TBL] [Abstract] [Full Text] [Related]
10. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract] [Full Text] [Related]
11. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract] [Full Text] [Related]
12. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract] [Full Text] [Related]
13. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract] [Full Text] [Related]
14. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract] [Full Text] [Related]
15. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
Manchanda R; Legood R; Pearce L; Menon U
Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
[TBL] [Abstract] [Full Text] [Related]
16. Prostate-Specific Antigen (psa)-Based Population Screening for Prostate cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract] [Full Text] [Related]
17. Prostate-specific antigen-based screening: controversy and guidelines.
Kim EH; Andriole GL
BMC Med; 2015 Mar; 13():61. PubMed ID: 25857320
[TBL] [Abstract] [Full Text] [Related]
18. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract] [Full Text] [Related]
19. Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.
Bian J; Li B; Kou XJ; Wang XN; Sun XX; Ming L
Asian Pac J Cancer Prev; 2014; 15(19):8409-11. PubMed ID: 25339038
[TBL] [Abstract] [Full Text] [Related]
20. To screen or nor to screen: the prostate cancer dilemma.
Stone NN; Crawford ED
Asian J Androl; 2015; 17(1):44-5. PubMed ID: 25337849
[TBL] [Abstract] [Full Text] [Related]
[Next]